Abstract The prevalence of non-communicable diseases like diabetes mellitus (DM) and hypertension (HTN) is growing worldwide. Both lead to nephropathy if not controlled effectively. Microalbuminuria (MAU) is recognized as an early predictor for nephropathy. Additionally, the timely detection of advanced glycation end products (AGEs) is also considered to be an important prognostic factor for diabetic nephropathies. Hence, screening for the early detection of MAU and AGEs would be an useful and relatively inexpensive laboratory test for early clinical diagnosis for the incidence of nephropathy in these diseases. This study was conducted in DM, HTN and pregnancy induced hypertensive (PIH) subjects. MAU and N e -Carboxymethyllysine (CML) levels were estimated by in-house RIA kits in the patient groups and controls, while the total AGEs level in serum was determined by ELISA. The levels of MAU, CML and AGE-BSA were observed to be significantly higher in DM, HTN and PIH subjects compared to controls (p \ 0.001). Increased serum CML and AGEs levels in DM, HTN and PIH subjects indicated ongoing glycemic damage and their susceptibility to develop renal complications.
Introduction
Systemic diseases like diabetes mellitus (DM) and hypertension (HTN) are on the increase all over the world due to sedentary lifestyles and improper dietary habits [1] . Both DM and HTN are often associated with nephropathy. Managing nephropathy can be a huge financial burden which can be unaffordable in developing countries like India [2] . Consequently, early detection of nephropathy when it is in reversible or therapeutically controllable stage is warranted to prevent further advancement of the impairment. Microalbuminuria (MAU) is a well-known predictor of nephropathy and cardiovascular disease (CVD) in DM and HTN [3] [4] [5] . The advanced glycation end products (AGEs) are also recognized as the early markers for renal injury in DM and HTN subjects recently. AGEs are formed by a non-enzymatic reaction between reducing sugars and free amino groups of structural and circulatory proteins. Initially Schiff's bases are formed followed by their rearrangement into Amadori products and finally they are irreversibly converted into AGEs. CML is a major AGE among others reported so far. The kidney is susceptible to AGEs-related impairment as it is the major site of AGEs clearance [6] [7] [8] . MAU is a condition where slightly elevated levels of albumin are excreted in urine, not detected by conventional dipstick-methods, in the absence of any urinary tract infection and acute illness. This represents a urinary albumin excretion rate of 30-300 mg/day equivalent to 30-300 lg/ml, assuming urine output of a liter per day. The pathophysiology underlying MAU in DM is related to hemodynamic alterations and AGEs-mediated alterations in the glomerular permeability. In essential hypertension, increased blood pressure load and increased systemic vascular permeability play a major role in pathogenetic mechanism leading to MAU. AGEs are also implicated in pathogenesis of HTN related nephropathy [9] . Additionally, MAU has been recognized as predictor of pregnancy induced hypertension (PIH) leading to preeclampsia (PE) [10] . AGEs have been implicated in the pathogenesis of PE [11] . Early diagnosis of nephropathy by MAU and elevated circulating AGEs by immunoassays would be more practicable and economical than using other available analytical techniques. RIAs were standardized for MAU as well as for CML as it is a major AGE-product. The estimation of MAU and CML by RIA will be helpful for clinicians in identifying and regular screening of highrisk subjects. Eventually, the timely reno-protective measures would certainly reduce incidence of nephropathy in DM, HTN and PIH subjects.
Materials and Methods
MAU and serum CML were assayed by in-house standardized RIA procedures [12] . The serum AGE-BSA levels were estimated by ELISA as per the manufacturer's instructions, using OxiSelect AGEs kit, Cat No. STA 317, from Cell Biolabs, Inc., USA, (www.cellbiolabs.com). Briefly, AGE-BSA standards and diluted serum were coated on protein binding microtitre ELISA plates. The AGE-proteins were probed with anti-AGE polyclonal antibody, followed by HRP-labeled secondary antibody. The AGE-protein in serum sample is determined by comparing with a standard curve prepared from AGE-BSA standards. Urinary protein was analyzed by Bayer's Uristix strips in morning urine samples. It is a semi quantitative dip stick method and is based on visual detection of the change in the colour of dye impregnated on the strip. The colour of the dye changes due to the chemical reaction between urinary protein and the dye. This test is not specific for albumin and measures total protein.
HbA1c was estimated by HPLC method in the Pathology Section of B.A.R.C. Hospital. This study included DM, HTN and pregnancy induced hypertensive (PIH) patients. Informed consent in writing was obtained from all the patients.
The ages of the DM subjects (n = 182) ranged from 14 to 70 years. The duration of diabetes in DM group ranged from 1 to 25 years. The age of the hypertensive patients (n = 50) ranged from 27 to 67 years. Their duration of hypertension ranged from 1 to 12 years. PIH (Pregnancy induced hypertensive) patients included women in their last trimester having BP C 140/90 mm Hg. Their ages ranged from 20 to 27 years. Five ml venous blood sample was collected from the patients in plain vacutainer tubes, serum was separated and used for determination of CML and AGE. Patients were asked to collect 50 ml urine sample from morning, first-voided urine in sterile plastic containers for estimating MAU. Pearson's correlation r and oneway ANOVA analysis was used for the Statistical evaluation of data.
Results
Radioimmunoassays for measuring urinary albumin and serum CML in patients' samples were standardized inhouse. The minimum detectable concentrations in the assays were 5, 0.01 and 0.1 lg/ml for MAU, CML and AGE-BSA respectively. The intra-and inter-assay variations was \10% for MAU and \15% for CML and AGE-BSA. The percent recovery of a known quantity of analyte, added to standards in the assay, was within 100 ± 15% for MAU-RIA and CML-RIA respectively.
MAU, CML and AGE-BSA levels were significantly higher in DM, HTN and PIH patients compared to control subjects ( Table 1 ). The MAU concentrations showed a skewed distribution and, hence, are expressed as median values. MAU was not detected in 19% of DM and 10% of HTN patients when tested by commercial Uristick strips while it was in measurable range when analysed by MAU-RIA. Prevalence of MAU was 30, 22 and 70% in DM, HTN and PIH subjects respectively.
HbA1C levels were 8 ± 2% in the DM group (n = 138). DM patients with MAU had HbA1C levels that were higher than the normal cut-off. The number of DM and HTN patients who were MAU-positive increased with duration of disease (Tables 2, 3 ). The mean HbA1C, CML and AGE-BSA levels showed gradual increase with duration of DM ( Table 2) . Over 90% of the normoalbuminuric diabetic (NAU-DM) subjects had higher CML and AGE-BSA levels. The DM, HTN and PIH patients were grouped on the basis of urinary albumin excretion i.e. as normoalbuminuric (NAU) and microalbuminuric (MAU) and their AGE-BSA compared. The mean AGE-BSA levels in MAU-DM subjects were significantly higher as compared to NAU-DM, however, there was no significant difference in CML elevation in these groups ( Table 4 ). The MAU-DM group had significant increase in AGE-BSA levels when compared to MAU-HTN and MAU-PIH group (p \ 0.01). The mean CML levels were significantly higher in MAU-HTN group when compared to NAU-HTN group (p \ 0.05). The extent of elevation in CML levels in MAU-DM and MAU-HTN was similar. No statistical difference between the NAU-PIH and MAU-PIH groups was observed.
Statistically significant correlation was observed between MAU and AGE-BSA levels in the subjects studied: In DM patients r = 0.51 (n = 163, p \ 0.001) was observed, and it was r = 0.37 (n = 50, p \ 0.01), r = 0.35 (n = 37, p \ 0.02) for HTN and PIH groups respectively. However, no correlation was found between MAU and CML, and AGE-BSA and CML levels.
Discussion
RIAs standardized in-house for MAU as well as for CML (a major AGE-product) was used in the study. The performance of both the assays were acceptable for diagnostic use in terms of sensitivity, specificity, analyte recovery and reproducibility. DM, HTN and PIH subjects with high MAU had significantly increased risk for nephropathy [3] [4] [5] . It can be expected that when MAU, CML and AGE-BSA are all significantly increased, the risk would be higher in DM patients. Many prospective studies have reported the importance of MAU levels as a diagnostic marker of nephropathy in DM, HTN subjects [13] [14] [15] [16] and of PE in PIH [10, 17] . The median and prevalence of MAU increased as the duration of DM and HTN increased, plausibly due to increased exposure to hyperglycemia in DM patients and hypertension load in HTN patients. The association of elevated serum AGEs with nephropathy has been shown in DM, HTN and PE subjects [7, 9, 11, [18] [19] [20] [21] [22] [23] . Studies estimating serum CML levels in HTN and PIH subjects are not reported, so far, in the literature. Increased serum AGE levels have been reported in hypertensive animal models too [9] . The mean AGE-BSA levels increased significantly with duration of diabetes in DM group and so did the percentage of subjects with higher AGE-BSA levels. Whereas, in HTN group, both mean CML and AGE-BSA levels showed a very small increase with duration of illness. The AGE-BSA levels represented total AGEs levels as the antibody used in the assay could detect multiple AGE structures. The total AGEs level are indicators of the AGEs formed mainly via hyperglycemia mediated advanced glycation as in DM and the CML levels are considered as a marker of oxidative stress rather than advanced glycation alone [24, 25] . This may be the possible reason for obtaining a significant increase in AGE-BSA rather than in CML levels with respect to time in DM subjects and for obtaining relatively better correlation between MAU i.e. marker of nephropathy and AGE-BSA levels in this study as well.
The increased AGEs levels above normal cut-off in normoalbuminuric (NAU) patient groups in this study indicate a clinically important finding. The increased serum AGEs may be an indicator of very initial stage of nephropathy where MAU is not yet evident. Such subjects should be followed-up clinically and managed to prevent development of MAU and subsequent nephropathy. When NAU and MAU patients' groups were compared, the total AGE levels were significantly higher in MAU-DM group than NAU-DM group as expected due to cumulative AGEproduction with progressive disease. Furthermore, AGE-BSA were significantly higher in MAU-DM as compared to MAU-HTN and MAU-PIH group (p \ 0.01). This indicated that AGEs formation increases profoundly in DM due to hyperglycemia as compared to non-hyperglycemic disorders like HTN and PIH. CML, which is an indicator of increased oxidative stress, was significantly higher in MAU-HTN group compared to NAU-HTN group indicating increased oxidative stress in former group. The extent of CML elevation was similar in MAU-DM and NAU-DM group showing similar oxidative stress in both the DM subgroups. The comparable CML in NAU-PIH and MAU-PIH groups indicates the shorter duration of oxidative distress in pregnancy compared to long-term diseases like DM and HTN.
As of now, it is not clear which of the AGEs formed has a higher probability for AGE-induced complications. Therefore, it may be appropriate to detect total AGEs formed rather than detecting a specific AGE-structure like CML. The serum CML or AGEs levels signify overall metabolic injury affecting renal as well as other tissues. Therefore, AGE-determination along with evaluation of the other markers of risk factors, including MAU and glomerular filtration rate (GFR), may give unequivocal indication about progression in diabetic as well as nondiabetic nephropathies. Also, more long-term studies would help determine the relevance of AGEs as early indicators of nephropathy in DM and HTN, and to know the burden of CML and total AGEs beyond which MAU becomes evident.
A lack of statistically significant correlation between MAU and CML and between CML and AGE-levels was observed in this study. This may be related to the several confounding factors like the effect of medical treatment, co-existing pathologies, variations in dietary AGEs-content and different immunoassay approaches used in this study.
Conclusion
Early diagnosis of nephropathy or evaluating its possibility by MAU and AGEs-detection is possible by immunoassays. Laboratories, which can process large numbers of samples in a short period using immunoassays, can play an important role in helping clinicians to manage DM and HTN patients. Indigenous assays using indigenous reagents can provide cost-effective screening assays, avoiding expensive imports. It will be helpful for the large numbers of DM and HTN patients in our country.
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